Can a diabetes drug improve joint replacement outcomes?

NCT ID NCT07755085

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether taking a GLP-1 medication (semaglutide) for at least six months before hip or knee replacement surgery can improve recovery and reduce complications in patients with obesity. Participants will be randomly assigned to receive either the medication plus behavioral support (diet, exercise, counseling) or a placebo with the same support. The study will track wound complications, weight loss, and mobility changes to see if this approach helps high-risk patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide (a GLP-1 receptor agonist) combined with structured behavioral modification (diet, exercise, counseling)
What this could lead to
If effective, this approach could reduce surgical complications and improve recovery for obese patients undergoing joint replacement, potentially leading to better standard care.
What could go wrong
This is a small pilot study, so results may not be conclusive. The medication may not reduce complications and could have side effects, and the behavioral program adds complexity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nova Scotia Health

    Dartmouth, Nova Scotia, B2Y 2N5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.